EcoDrugPlus

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSOMEG00000016511
Gene Symbol: LOC112148278
4 Cross references
209 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSOMEG00000017936
Gene Symbol: FGFR2
3 Cross references
214 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSOMEG00000004574
Gene Symbol: FGFR3
3 Cross references
193 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSOMEG00000008856
Gene Symbol: FLT4
1 Cross references
193 Possible Orthologues:

Fms Related Tyrosine Kinase 1

Ensembl ID : ENSOMEG00000007898
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSOMEG00000001007
Gene Symbol: FOLH1B
3 Cross references
339 Possible Orthologues:

Folate Receptor Beta-Like

Ensembl ID : ENSOMEG00000002791
Gene Symbol: LOC112149905
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSOMEG00000020641
Gene Symbol: LOC112143761
2 Cross references
334 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSOMEG00000020665
Gene Symbol: LOC112143782
2 Cross references
331 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSOMEG00000003439
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSOMEG00000014041
Gene Symbol: GLA
1 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSOMEG00000000627
Gene Symbol: LOC112148464
3 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).